
Allarity Therapeutics (ALLR) Stock Forecast & Price Target
Allarity Therapeutics (ALLR) Analyst Ratings
Bulls say
Allarity Therapeutics Inc is positioned favorably due to its attractive current valuation, with potential significant upside as indicated by a revised net present value (NPV) analysis that sees the value enhanced to $9.25 per share. The company’s drug candidate, stenoparib, has demonstrated promising and durable clinical benefits for patients suffering from advanced recurrent ovarian cancer, addressing a substantial unmet medical need. Finally, the use of proprietary Drug Response Predictor (DRP) technology enhances patient selection, which is expected to improve clinical outcomes and bolster the company’s advancement in the competitive oncology market.
Bears say
Allarity Therapeutics Inc reported a net loss of $2.37 million, equating to an earnings per share (EPS) of $(0.15), which was better than the estimated EPS of $(0.21). Despite the potential upside of the company's innovative therapeutic developments and proprietary Drug Response Predictor technology, substantial risks remain, including liquidity concerns and uncertainties regarding clinical trial outcomes. Additionally, challenges related to regulatory approvals, commercialization, competition, and macroeconomic factors contribute to a negative outlook for the company's stock performance.
This aggregate rating is based on analysts' research of Allarity Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Allarity Therapeutics (ALLR) Analyst Forecast & Price Prediction
Start investing in Allarity Therapeutics (ALLR)
Order type
Buy in
Order amount
Est. shares
0 shares